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Background and Objectives: Treatment guidelines emphasize
patients’ readiness for transitioning from opiate substitution
treatment (OST) to opiate withdrawal and abstinence. Psychological
preparedness indicators for this transition were examined.
Methods: Patients (all male) were recruited from three treatment
settings: prison, an inpatient detoxification unit, and an outpatient
clinic. Time 1 (T1) was admission to methadone‐assisted
withdrawal in all settings. Time 2 (T2) was a 6‐month follow‐up.
With n= 24 at T1 for each group (N= 72), a battery of instruments
relevant to psychological preparedness was administered.
Results: At T1, inpatients had higher self‐efficacy beliefs for
successful treatment completion than prison patients. For patients
contactable at T2, T1 self‐efficacy positively predicted T2 opiate
abstinence. No other variable improved prediction. T1
SOCRATES (Stages of Change Readiness and Treatment
Eagerness Scale) ambivalence scores, age, and lifetime heroin
use duration predicted maintenance of contact or not with
treatment services and contactability by the researcher.
Measures of mood did not differ between groups at T1 or
predict T2 outcomes.
Discussion and Conclusions: Self‐efficacy beliefs are a potentially
useful indicator of readiness for transitioning from OST to a
medically assisted opiate withdrawal and subsequent abstinence.
Ambivalence regarding change, age, and lifetime heroin use
duration are potentially useful predictors of patients maintaining
contact with services, and of being retained in research.
Scientific Significance: These findings advance existing literature
and knowledge by highlighting the importance of self‐efficacy in
psychological preparedness for opiate abstinence, and the predictive
utility to clinicians of this and other variables measurable at
admission, in the clinical management of opiate users. (© 2020 The
Authors. The American Journal on Addictions published by Wiley
Periodicals LLC on behalf of The American Academy of Addiction
Psychiatry (AAAP);00:00–00)
INTRODUCTION
Interventions targeting opiate abstinence pose challenges to
patients arising from withdrawal symptoms,1 followed by
longer‐term challenges around establishing an opiate‐free life.
The latter may include craving to use opiates again,2 pressure to
relapse from opiate misusing acquaintances,3 and the need
to replace opiate misuse as a coping mechanism for problems
in living.4 Opiate abstinence treatments occur in a variety
of settings including hospital wards, outpatient clinics, and
prisons. These may differ regarding the extent of psychosocial
support available, with potential consequences for patients’
affective states and commitment to treatment objectives. UK
treatment guidelines emphasize the importance of patients’
preparedness for opiate withdrawal, and their active
engagement in treatment decisions, particularly regarding
the discontinuation of opiate substitution treatment (OST)
in favor of a withdrawal regime.5,6 However, pressure
from governmental sources encourages abstinence‐orientated
treatments wherever possible. Concerns have consequently
arisen regarding adverse outcomes due to patients being
channeled toward abstinence without sufficient preparation
and commitment to this step, particularly where the withdrawal
stage will occur in prison.7 In other governmental jurisdictions,
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including the United States, OST is not generally available in
prisons despite evidence of its effectiveness. Opiate withdrawal
is, therefore, enforced regardless of patient preparedness,
with a consequent decreased likelihood of future treatment
engagement and an increased likelihood of further dangerous
opiate misuse.8,9
Self‐efficacy is an element of psychological preparedness
for addiction treatment, which has been examined in
relation to a variety of substances across treatment
contexts.10‐12 Self‐efficacy is generally understood to refer
to a person’s belief in their ability to achieve specific
goals.13 For addiction treatment, this implies attaining
treatment objectives including, where appropriate,
abstinence from a drug of addiction. Where OST has
taken the form of methadone maintenance there is evidence
that self‐efficacy is positively related to achieving treatment
goals such as enhanced life stability and avoiding illegal
drugs.14‐17
For abstinence‐orientated treatment, there are few
studies examining the predictive value of self‐efficacy
at treatment admission for subsequent outcomes.
Psychometric measures of admission self‐efficacy for
outpatient methadone withdrawal have been shown to
remain stable during the stabilization stage of medication,
but to diminish progressively with tapering methadone
doses.18 Illicit opiate use in this sample increased during
the methadone taper. Another study reported that higher
admission self‐efficacy for a brief inpatient methadone
detoxification predicted a greater likelihood of refusing
post‐detoxification medication to maintain abstinence.19
However, the success rate for maintaining abstinence was
not reported, and this study measured self‐efficacy using
an ad hoc scale comprising one question. Confidence in
one’s ability to achieve treatment goals has sometimes
been reported as being synonymous with self‐efficacy.
Visual analogue scale admission measures of confidence
for successful treatment completion have positively
predicted heroin abstinence 3 months later, but not
inpatient methadone detoxification completion.20,21
Overall, the lack of consistent use of psychometrically
validated measures of self‐efficacy in studies of opiate
withdrawal and abstinence weakens the conclusions
possible regarding its role as an outcome predictor for
such treatment.
The present multisite study compared patients’ self‐
efficacy scores from a validated psychometric instrument at
admission for methadone withdrawal (T1) in three treatment
settings. The predictive ability of these scores was
subsequently tested at 6‐month follow‐up (T2) for
treatment outcomes, and also for maintenance of contact
with T1 treatment services. Predictive ability for the latter
outcome was tested due to the risk of contact being lost with
patients following OST termination, and the negative
consequences which can follow.8,9 The treatment settings
were a prison, a hospital inpatient unit, and a community‐
based clinic. Self‐efficacy does not exist in a psychological
vacuum, and two other aspects of preparedness for treatment
examined were mood state, and attributions for treatment
outcomes. It may be noted that depression has been
associated with on‐going opiate misuse,19,22 while
attributions emphasizing taking responsibility for one’s
treatment progress have been related to favorable
outcomes.23,24 However, such attributions are frequently
measured retrospectively, rather than being potential
predictors as in this present study. Finally, as variables
concerning criminal activity and judicial consequences can
impact upon heroin users differently,25‐27 the relationship of
such variables to measures of psychological preparedness
was also examined.
METHOD
Design and Participants
Treatment setting at T1 was a between‐participant
independent variable comprising three patient/participant
groups recruited from facilities in the north‐west of
England. The prison group (PG) was recruited from
HMP Liverpool, the inpatient group (IG) from a National
Health Service (NHS) facility, and the community‐based
treatment group (CG) from an NHS drug dependency
clinic. As access to incarcerated patients was only possible
in a male prison, only male participants were recruited in
the other treatment settings to avoid gender becoming a
confounding variable across settings. All patients were
within the first week of a methadone programme orientated
toward withdrawal at T1. Recruitment to the study was
based upon successive admissions, subject to willingness
to participate, and interviewer availability. The total
sample for the study at T1 was N = 72, with n = 24 for
each group. The GPower software programme28 indicated
that n = 24 would provide power at 0.85 for large effects
(ie, f = 0.40), for intergroup comparisons comprising three
groups with a conventional alpha level of P ≤ .05.
Additionally, the total sample of N = 72 would be
sufficient for power at 0.85 for two‐tailed correlations
with an effect size of r = .35 and a conventional α level of
P ≤ .05. Decisions concerning regression analyses using
T2 variables as outcomes were made on a post hoc basis,
subject to the sample size available.
Treatment Protocols
All three treatment settings conformed to UK guidelines
for treating drug misuse5,6 regarding OST, and the need for
patient readiness for opiate withdrawal and long‐term
abstinence. Methadone was prescribed in response to the
needs of the individual in all treatment settings, with dosages
being dependent upon the severity of withdrawal symptoms.
Starting doses were typically in the range of 30 to 50 mg of
oral methadone daily. There was a target reduction rate of
2 mg per week for the PG, while the target completion time
for the IG was between 3 and 4 weeks. The variability in the
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reduction rate for the CG, in response to patient need and
distress prevents the reporting of an average or notional rate.
Measures
Psychological Preparedness
Psychological preparedness for treatment at T1 was
assessed by the following instruments.
Stages of Change Readiness and Treatment Eagerness
Scale (SOCRATES 8D). This self‐completion instrument
yields scores on three scales representing, respectively,
recognition of a drug problem, ambivalence regarding drug
use, and taking steps regarding drug use.29 Higher scores
indicated higher levels of these properties.
Drug‐Taking Confidence Questionnaire (DTCQ‐8). The
DTCQ‐830 is a self‐completion measure of confidence for
avoiding drug use across eight situations. Total scores pooled
across all situations were used, with higher scores indicating
higher self‐efficacy.
Confidence for Treatment Scale (CTS). The CTS21 gave
patients the following question and instruction: “How
confident are you that you will be drug‐free following your
drug treatment. Place a cross on the line below.” The scale
comprised a horizontal line 100 mm in length, with the left
pole labeled “No confidence,” and the right pole labeled
“extremely confident.” Scores were recorded in millimeters
measured from the left pole. Higher scores indicated higher
confidence.
Attribution of Treatment Responsibility Scales (ATRS).
Based upon the format used by Eiser et al,31 patients were
presented with the question “Many heroin users fail when they
try to give up the drug because:” to which they responded on
each of five scales. Each scale represented one pole of two
bipolar dimensions, these being “internal attribution‐external
attribution” and “stable attribution‐unstable attribution.” The
five scales presented to participants were: (A) “It is just too
difficult for them”; (B) “Because they do not try hard enough”;
(C) “Because they do not know the best way to set about it”;
(D) “Because of the kind of people they are”; and (E) “Because
of bad luck” (external and unstable). The response format for
each scale was “1” (“strongly disagree”), “2” (“disagree”), “3”
(“neither agree nor disagree”), “4” (“agree”), and “5”
(“strongly agree”). Internality scores were calculated by
summing the ratings of (B) and (D), and subtracting from
this sum, the sum of the ratings of (A) and (C) (ie,
Internality= (B+D) − (A+C)). For stability scores the
calculation was as follows: Stability= (A+D) − (B+C).
Depression Anxiety Stress Scales (DASS‐21). This
instrument comprises 21 items, generating subscale
measures for depression, anxiety, and stress. Higher scores
indicated higher levels of these scale properties.32
Background Measures
The Addiction Severity Index (ASI)33 recorded patients’
demographic details, family situations, histories of illegal
drug consumption, treatment for drug‐related problems, and
engagement in criminal behavior.
Procedure
T1 data were collected through structured interviews with
patients conducted by a member of the research team (SJ) in
a confidential location within the respective treatment
settings. Written informed consent was obtained from all
patients. Where possible, T2 data were also obtained through
interviews conducted in the same facility as T1 interviews.
However, T2 interviews were difficult to arrange due to
constantly changing residential addresses for patients in the
community, which included those discharged from hospital
or prison since T1. Consequently, the presentation of T2 data
are limited to self‐reports of the use or not of heroin since T1,
and patients contact status with the service where the T1
withdrawal had started.
Ethical Scrutiny
The data collection procedure was approved by the relevant
NHS Research Ethics Committees, prison authorities, and the
research ethics scrutiny procedures of Edge Hill University.
The rights of all patients regarding confidentiality, withdrawal
from the study, anonymity, and protection from harm while
participating were respected at all times. Ethical approval did
not include access to records of criminal offenses or to patients’
treatment notes. However, the Participant Information Sheet
emphasized that the researcher had no role in making treatment
decisions, and would respect the confidentiality of their data in
relation to both their clinicians and legal authorities. It was
emphasized, therefore, that there were no incentives to
misinform the researcher. Data were stored in accordance
with the UK Data Protection Act 1998.
Analytic Strategy
Intergroup comparisons were primarily conducted using
between‐participants analysis of variances (ANOVAs), with
post hoc pairwise comparisons being evaluated as two‐tailed
against a Bonferroni adjusted α level of P≤ .017. Where the
assumptions of parametric ANOVA were violated,
nonparametric Kruskal‐Wallis ANOVAs were conducted,
with post hoc comparisons utilizing the Mann‐Whitney U test
being evaluated in the same way. Relevant correlational
analyses were conducted across the whole sample. Logistic
regression analyses were conducted on two dependent
variables (DV) measured at T2, these being “heroin use or
not since T1,” and “contact maintained maintenance or not
with T1 treatment services.” The power and validity of these
analyses were protected by minimizing the number of
independent variables included as predictors using
hierarchical variable entry, so that the ratio of participants
per predictor remained as far below the accepted maximum
criterion of 10:1 as possible.34,35
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RESULTS
Background and Drug Misuse‐Related
Variables at T1
The mean period of current incarceration for PG
patients at T1 was 6.63 months (SD = 8.58 months).
Table 1 (Sections A to C) summarizes results for
background and drug misuse variables. The post hoc
comparisons show that the PG had committed more drug
offenses than the IG. PG patients had also committed more
burglaries and had longer total imprisonment durations
than the other groups. Regarding drug consumption, the
PG reported less heroin consumption than the other groups
in the 30 days prior to T1, but reported the highest
prevalence of cocaine consumption within this timeframe.
CG patients were receiving significantly higher daily
methadone doses at T1 than the other groups.
Treatment Preparedness Variables at T1
Table 1 (Section D) summarizes results for the treatment
preparedness variables at T1. The IG scored significantly higher
than the PG on both the DTCQ‐8 and CTS, while also scoring
significantly higher on the SOCRATES problem recognition
scale than the CG. There were no significant intergroup
differences on the other SOCRATES scales, or for any of the
mood and attribution scales. Table 2 summarizes the significant
correlations between treatment preparedness variables and
demographic, crime‐related, and drug misuse variables, across
the whole sample. Age was negatively correlated with both the
SOCRATES ambivalence and taking steps scales, while self‐
efficacy was negatively correlated with lifetime duration in
prison, and the number of days in the previous 30 days on which
heroin and methadone, respectively, had been used.
Heroin Use Between T1 and T2
Sample attrition meant that T2 data were only available from
48 patients comprising 13 PG, 18 IG, and 17 CG patients. Three
of the 24 patients lost to the study at T2 were contactable but
declined to participate, with contact being lost with the
remainder (ie, n= 21; 29.2% of the T1 sample) by both the
researcher and the treatment services supervising the withdrawal
at T1. Only 15 of the 48 patients retained at T2 reported having
remained heroin‐free since T1, with 10 of these being either in
prison or receiving continuing medication from drug services. Of
the 33 patients who had used heroin since T1, 29 were either in
prison or receiving continuing support from drug services.
Where data were available, use of heroin or not since T1 was not
associated with treatment setting (χ2[2,N= 48]= 4.778, ns).
Hierarchical logistic regression analyses for the
prediction of heroin use or not since T1 were conducted
with a limit of two independent variables at one time to
preserve statistical power. Of the five variables in Table 3
(Section A) showing significant (or near to significant)
T2 differences in measures taken at admission, CTS
ratings were excluded from the regression analyses due to
high correlations with the other variables. The DTCQ‐8
scores were entered in model 1, and yielded a significant
improvement in outcome prediction (ie, compared with
random prediction (model χ 2[1, N = 48] = 4.831, P = .028,
−2 log likelihood = 54.794, Cox and Snell R2 = .096).
Model 2 comprised, successively, the other variables in
Table 3 (Section A), one at a time. None of these variables
significantly improved the prediction of relapse compared
to Model 1. Further details of model 1 are shown in
Table 4 (Section A) where the positive B coefficient for
DTCQ‐8 scores indicates that higher scores were related
to an increased likelihood of no further heroin use
since T1.
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TABLE 2. Significant correlations at T1 for the treatment preparedness variables with variables in Table 1 recording demographic status, drug use,
and criminal engagement
Treatment preparedness variable Variable from Table 1 Correlationa
SOCRATES: ambivalence Age r(70)= −.245, P= .041
SOCRATES: taking steps Age r(70)= −.270, P= .024
Number of days of heroin use in the 30 days prior to T1 rs(72)= −.278, P= .018
DTCQ‐8 Lifetime duration in prison rs(72)= −.230, P= .052
Number of days of heroin use in the 30 days prior to T1 rs(72)= −.239, P= .044
Number of days of methadone use in the 30 days prior to T1 rs(72)= −.405, P< .000
ATRS: luck Daily methadone doses at T1 rs(65)= .344, P= .005
Number of days of methadone use in the 30 days prior to T1 rs(72)= −.232, P= .050
DASS‐21 anxiety Number of thefts from shops rs(70)= −.240, P= .046
DASS‐21 stress Number of thefts from shops rs(70)= −.316, P= .008
Number of burglaries rs(70)= −.228, P= .057
CTS Estimated lifetime duration of heroin use rs(72)= −.229, P= .052
Three correlations are also reported here with P values between .05 and .06.
ATRS=Attribution of Treatment Responsibility Scales; CTS=Confidence for Treatment Scale; DASS‐21=Depression Anxiety Stress Scales;
DTCQ‐8=Drug‐Taking Confidence Questionnaire; SOCRATES= Stages of Change Readiness and Treatment Eagerness Scale.
aAll probability values reported here are two‐tailed.
Maintenance of Contact With T1 Treatment
Services at T2
Patients’ maintenance of contact with T1 treatment services
was not associated with treatment setting (χ2[2,N= 72]= 2.625,
ns). Table 3 (Section B) shows the three variables with
significant T2 differences in measures taken at admission
between patients maintaining contact or not. As there were
only three variables showing significant differences, they were
entered as a block of independent variables in a logistic
regression analysis using maintenance of contact or not as
the dichotomous DV. This yielded a significant improvement
in the prediction of contact maintenance T2 (model
χ2[1,N= 68]= 11.990, P= .007, −2 log likelihood= 70.399,
Cox and Snell R2= .162). Further details of this model are
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TABLE 3. Variables measures at T1 (means and (SD)) showing significant differences for (A) T2 relapse or not and (B) maintenance of contact or
not with T1 services and the researcher at T2
A. Variables measured at T1 showing significant differences between relapse or not at T2
Variable
No heroin use since
T1 (n= 15)
Heroin used since
T1 (n= 33) Significancea
SOCRATES taking steps 35.60 (3.25) 33.49 (3.52) t(46)= −1.975, P= .054,
d= 0.625
DTCQ‐8 570.67 (252.18) 380.61 (286.60) t(46)= −2.207, P= .032,
d= 0.704
CTS ratings 80.20 (27.88) 58.70 (30.96) U= 136.00, P= .012,
Number of days on which heroin was
used in the 30 days prior to T1
3.93 (8.23) 11.70 (12.70) U= 152.00, P= .025
Number of days in the previous 30 days at
T1 in receipt of methadone treatment
19.80 (14.26) 25.90 (9.92) U= 185.00, P= .058
B. Variables measured at T1 showing significant differences between patients maintaining contact or not with T1 services and the
researcher at T2
Variable Contactable at T2 (n= 48) Not contactable at T2 (n= 21) Significancea
Age 40.77 (6.01) 36.00 (5.27)b t(66)= 2.699, P= .009, d= 0.738
Lifetime use of heroin, y 16.63 (7.33) 11.76 (9.76) t(67)= 2.286, P= .025, d= 0.564
SOCRATES: ambivalence 15.92 (2.01) 17.05 (2.54) t(67)= −2.146, P= .035, d= 0.494
CTS= Confidence for Treatment Scale; DTCQ‐8=Drug‐Taking Confidence Questionnaire; SOCRATES= Stages of Change Readiness and Treatment
Eagerness Scale.
aAll probability values are two‐tailed.
bn= 20 for this comparison.
TABLE 4. Details of the logistic regression analysis models for (A) predicting heroin use or not at T2 and (B) maintenance of contact or not with T1
services and the researcher at T2
Variable B SE Wald χ2 df Sig.
Odds
ratio (eB)
A. Dependent variable: Heroin used= 0; heroin not used=1
DTCQ‐8 0.003 0.001 4.247 1 .039 1.003
Constant −2.026 0.728 7.747 1 .005 0.132
B. Dependent variable: Contact maintained= 0; contact lost= 1
Age −0.088 0.056 2.457 1 0.117 0.916
Heroin
lifetime use
−0.047 0.038 1.561 1 0.211 0.954
SOCRATES:
ambivalence
0.246 0.144 2.929 1 0.087 1.278
Constant −0.855 3.338 0.066 1 0.798 0.425
CTS= Confidence for Treatment Scale; DTCQ‐8=Drug‐Taking Confidence Questionnaire; SOCRATES= Stages of Change Readiness and Treatment
Eagerness Scale.
shown in Table 4 (Section B). None of these independent
variables had significant Wald χ2 values.
DISCUSSION
The present findings show that self‐efficacy measured at
T1 by the DTCQ‐830 was an effective predictor of subsequent
self‐reported heroin use or not at a 6‐month follow‐up.
T1 intergroup comparisons showed that the IG scored
significantly more highly than the PG on this measure, and
also on the CTS. This result adds to the existing literature
concerning the predictive relationship of self‐efficacy and
confidence measures for successful treatment completion, to
outcomes concerning methadone withdrawal and the
maintenance of abstinence.18‐21 Of particular note is that
these findings came from a robust psychometric instrument
for measuring self‐efficacy rather than an ad hoc scale.19,30
These results suggest that self‐efficacy is a measurable
variable potentially usable by clinicians as an indicator of
patients’ preparedness for completing a methadone
withdrawal programme and remaining heroin‐free. Its use
as such would, however, need to be as part of a battery of
indicators informing clinical judgment regarding patients’
preparedness for opiate abstinence and the gradual removal
of OST, in accordance with clinical guidelines.5,6 As the
present data do not indicate whether patients high in self‐
efficacy sought an inpatient setting, whether the inpatient
setting boosted patients’ self‐efficacy, or whether a
synergistic interaction of these two explanations occurred,
further research is required to examine the implications for
clinical practice regarding the effective development of
patients’ self‐efficacy across different treatment settings, in
addition to the use in practice of self‐efficacy measures as
indicators of treatment preparedness.
Psychological preparedness for opiate withdrawal and
abstinence is a complex construct where self‐efficacy does
not function alone. DTCQ‐8 scores were negatively
correlated with methadone treatment duration in the
30 days prior to T1. This may reflect a need to obtain
sufficient personal and lifestyle stability through OST before
withdrawal and abstinence become conscionable objectives
to patients, thus reflecting the preparedness required for
ceasing OST highlighted in clinical guidelines.5,6 The strong
positive correlation between T1 methadone doses and
attributions to luck for treatment success may similarly
reflect a lack of preparedness, and a risk of the negative
outcomes associated with OST termination without adequate
preparation.8,9 Psychological preparedness is also related to
the broader social context of patients’ lives, as shown by the
negative correlation (approaching statistical significance)
between lifetime duration in prison and both DTCQ‐8 and
CTS scores. The PG scored worse on both of these
preparedness variables than the IG. This suggests that
limitations to drug availability through being in prison were
not associated with enhancing treatment preparedness, which
would be consistent with the negative consequences of
premature OST termination in prison reported elsewhere.
Prison incarceration has been shown to weaken relationships
with people and activities not associated with crime, and to
reduce prospects for legitimate employment.27 Such
consequences may be related negatively to treatment
preparedness, which, in turn, highlights the need for an
integrated network of clinical and social care provision
for patients with addiction problems.5,6 In summary, low
DTCQ‐8 scores may indicate the appropriateness of deferring
OST termination and the initiation of opiate withdrawal, in
favor of interventions to raise self‐efficacy for a subsequent
withdrawal.
This study provided no evidence of emotional states
predicting outcomes for methadone withdrawal and
abstinence, despite evidence for emotions playing an
important role in addictive behaviors.19,22 This role may
not, therefore, include mediation of outcomes for specific
withdrawal episodes. The lack of a difference in depression
between the PG and the other groups at T1 is noteworthy,
given the constraints of a prison environment. Additionally,
no relationship between T1 attributions for treatment
outcomes, and subsequent actual outcomes were found.
Although this suggests that such attributions at admission do
not have predictive value, this does not limit the indicative
value of attributions for progress and outcomes recorded later
in the treatment process.23,24
OST termination can lead to loss of contact with treatment
services and negative outcomes arising from continued opiate
use.8,9 Although no variables concerning methadone
treatment were related to maintaining contact or not with
T1 services in the present sample, higher SOCRATES
ambivalence scores and younger age were related to this
outcome. These relationships could indicate a lack of
preparedness for the opiate abstinence treatment available.
For patients who remained in contact with T1 services, these
two variables, which were negatively correlated with each
other, were not related to reported heroin use between T1 and
T2. Their role as predictor variables may therefore be limited
to maintaining contact or not with services.
This study has some important limitations. Sample
attrition was a challenge to T2 data collection, with some
nonsignificant results possibly being due to low statistical
power. However, attention to maintaining statistical power in
the logistic regression analyses did lead to meaningful
findings. As only male participants were studied, further
research is required concerning preparedness indicators for
comparable interventions for female patients. There was also
reliance on self‐reported data regarding drug use and crime.
However, this is not uncommon in the literature.
Toxicological verification of abstinence is not always
possible, and may not be ethically desirable following
treatment termination with regard to maintaining mutual
respect between former patients and professionals.
In conclusion, this study highlighted self‐efficacy
beliefs for treatment outcomes as potential predictors for
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opiate withdrawal modified by methadone and subsequent
abstinence. Patients’ age and ambivalence regarding
change emerged as potential predictors for maintaining
contact with treatment services.
This study was part of a successful partially self‐funded
PhD project undertaken by the lead author (SJ). Additional
financial support was provided by the Faculty of Health and
Social Care at Edge Hill University.
The research time would like to acknowledge the
assistance of Dr Phillip Gichuru, medical statistician in the
Faculty of Health, Social Care and Medicine at Edge Hill
University, with the statistical analyses of this study.
Declaration of Interest
The authors report no conflicts of interest. The authors alone
are responsible for the content and writing of this paper.
REFERENCES
1. Wesson DR, Ling W. The Clinical Opiate Withdrawal Scale (COWS).
J Psychoactive Drugs. 2003;35:253‐259. https://doi.org/10.1080/02791072.
2003.10400007
2. Tasić JK, Valkanou MK, Đukanović B, et al. Relapse risk factors in
heroin addicts treated with naltrexone and naltrexone‐behavioural
psychotherapy. Int J Ment Health Ad. 2018;16:351‐365. https://doi.
org/10.1007/s11469‐017‐9782‐7
3. Liu S, Li L, Shen W, et al. Scopolamine detoxification technique for
heroin dependence: a randomized trial. CNS Drugs. 2013;27:1093‐1102.
4. Hammerbacher M, Lyvers M. Factors associated with relapse among
clients in Australian substance disorder treatment facilities. J Subst Use.
2006;11:387‐394. https://doi.org/10.1080/14659890600708266
5. Department of Health (England) and Devolved Administrations. Drug
Misuse and Dependence: UK Guidelines on Clinical Management.
London: Department of Health (England), the Scottish Government,
Welsh Assembly Government and Northern Ireland Executive; 2007. http://
webarchive.nationalarchives.gov.uk/20170807160700/; http://www.nta.
nhs.uk/uploads/clinical_guidelines_2007.pdf. Accessed 31 January 2018.
6. Clinical Guidelines on Drug Misuse and Dependence Update 2017
Independent Expert Working Group. Drug misuse and dependence: UK
guidelines on clinical management. London: Department of Health; 2017.
https://www.gov.uk/government/uploads/system/uploads/attachment_data/
file/668611/clinical_guidelines_2017.pdf. Accessed 31 January 2018.
7. House of Commons. Home affairs committee—Ninth report. Drugs:
breaking the cycle. https://publications.parliament.uk/pa/cm201213/
cmselect/cmhaff/184/18402.htm. Accessed 31 May 2018.
8. Maradiaga JA, Nahvi S, Cunningham CO, et al. “I kicked the hard way.
I got incarcerated.” Withdrawal from methadone during incarceration
and subsequent aversion to medication assisted treatments. J Subst
Abuse Treat. 2016;62:49‐54.
9. Rich JD, McKenzie M, Larney S, et al. Methadone continuation versus
forced withdrawal on incarceration in a combined US prison and jail: a
randomised, open‐label trial. Lancet. 2015;386:350‐359.
10. Disbury KL, Kopak AM, Dean LV, et al. Pre‐ to posttreatment
differences in measures of risk of relapse and reoffending for
participants of RAPt’s 6‐week programs. J Offender Rehabil.
2015;54:556‐584. https://doi.org/10.1080/10509674.2015.1087443
11. Doyle SR, Donovan DM. Applying an ensemble classification tree
approach to the prediction of completion of a 12‐step facilitation
intervention with stimulant abusers. Psychol Addict Behav.
2014;28:1127‐1143. https://doi.org/10.1037/a0037235
12. Kouimtsidis C, Reynolds M, Coulton S, et al. How does cognitive
behaviour therapy work with opioid‐dependent clients? Results of the
UKCBTMM study. Drug Educ Prev Policy. 2012;19:253‐258. https://
doi.org/10.3109/09687637.2011.579194
13. Bandura A. Perceived self‐efficacy in the exercise of personal agency.
Psychologist. 1989;2:411‐424.
14. Ayres R, Ingram J, Rees A, et al. Enhancing motivation within a rapid
opioid substitution treatment feasibility RCT: a nested qualitative study.
Subst Abuse Treat Prev Policy. 2014;9:44.
15. Li L, Wu Z, Liang LJ, et al. An intervention targeting service providers
and clients for methadone maintenance in China: a cluster‐randomised
trial. Addiction. 2013;108:356‐366. https://doi.org/10.1111/j.1360‐0443.
2012.04020.x
16. Wong EC, Longshore D. Ethnic identity, spirituality, and self‐efficacy
influences on treatment outcomes among Hispanic American methadone
maintenance clients. J Ethn Subst Abuse. 2008;7:328‐340. https://doi.
org/10.1080/15332640802313478
17. Barta WD, Kurth ME, Stein MD, et al. Craving and self‐efficacy in the
first five weeks of methadone maintenance therapy: a daily process
study. J Stud Alcohol Drugs. 2009;70:735‐740.
18. Reilly PM, Sees KL, Shopshire MS, et al. Self‐efficacy and illicit opioid
use in a 180‐day methadone detoxification treatment. J Consult Clin
Psychol. 1995;63:158‐162.
19. Kenny SR, Bailey GL, Anderson BJ, et al. Heroin refusal self‐efficacy
and preference for medication‐assisted treatment after inpatient
detoxification. Addict Behav. 2017;73:124‐128.
20. Murphy PN, Bentall RP. Opiate withdrawal outcome: the predictive
ability of admission measures of motivation, self‐efficacy, and lifestyle
stability. Subst Use Misuse. 1997;32:1587‐1597.
21. Murphy PN, Bentall RP, Ryley LD, et al. Predicting post‐discharge
opiate abstinence from admission measures of motivation and
confidence. Psychol Addict Behav. 2003;17:167‐170.
22. Bouvier BA, Kinnard EN, Yedinak JL, et al. Prevalence and correlates
of depressive symptomology among young adults who use prescription
opioids non‐medically. J Psychoactive Drugs. 2019;51:441‐452. https://
doi.org/10.1080/02791072.2019.1654151
23. Ravenna M, Hölzl E, Kirchler E, et al. Drug addicts in therapy—changes
in life space in the course of one year. J Community Appl Soc Psychol.
2002;12:353‐368.
24. Flynn PM, Joe GW, Broome KM, et al. Looking back on cocaine
dependence: reasons for recovery. Am J Addict. 12, 2003:398‐411.
25. Best D, Day E, Homayoun S, et al. Treatment retention in the Drug
Intervention Programme: do primary drug users fare better than primary
offenders? Drug Educ Prev Policy. 2008;15:201‐209. https://doi.org/10.
1080/09687630701198165
26. Nurco DN. A long‐term program of research on drug use and crime.
Subst Use Misuse. 1998;33:1817‐1837. https://doi.org/10.3109/
10826089809059323
27. Weaver B, Armstrong S. User views of punishment—the dynamics of
community‐based punishment: insider views from the outside. The Scottish
Centre for Crime and Justice Research. http://www.sccjr.ac.uk/wp‐content/
uploads/2012/11/Report_2011_03_User_Views_of_Punishment‐1.pdf
28. Faul F, Erdfelder E, Lang A‐G, et al. G*Power 3: a flexible statistical
power analysis program for the social, behavioral, and biomedical
sciences. Behav Res Methods. 39, 2007:175‐191.
29. Miller WR, Tonigan JS. Assessing drinkers’ motivation to change: the
States of Change Readiness and Treatment Eagerness Scale
(SOCRATES). Psychol Addict Behav. 1996;10:81‐89.
30. Sklar SM, Turner NE. A brief measure for the assessment of coping
self‐efficacy. Addiction. 1999;94:723‐729.
31. Eiser JR, van der Plight J, Raw M, et al. Trying to stop smoking: effects
of perceived addiction, attribution for failure, and expectancy of success.
J Behav Med. 8, 1985:321‐341.
9Jones et al. Month 2020
32. Henry JD, Crawford JR. The short formed version of the Depression
Anxiety Stress Scales (DASS‐21): construct validity and normative
data in a large non‐clinical sample. Br J Clin Psychol. 44, 2005:
227‐239.
33. McLellan AT, Cacciola JC, Alterman AI, et al. The Addiction Severity Index
at 25: origins, contributions and transitions. Am J Addict. 2006;15:113‐124.
34. Perduzzi P, Concato J, Kemper E, et al. A simulation study of the
number of events per variable in logistic regression analysis. J Clin
Epidemiol. 1996;49:1373‐1379.
35. Vittinghoff E, McCulloch CE. Relaxing the rule of ten events
per variable in logistic and Cox regression. Am J Epidemiol.
2006;2006:710‐718.
10 Psychological Preparedness for Opiate Withdrawal Month 2020
